An FDA advisory committee has voted favorably to approve Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide Type II diabetes drug.
Shares in the insulin maker were up 2% in after-hours activity today, trading at $50.13 apiece.
Get the full story at our sister site, Drug Delivery Business News.